Information has been received from a registered nurse concerning a 71 year old male who on 16-JAN-2009 was vaccinated with a dose of ZOSTAVAX (Merck), subcutaneously. On 19-JAN-2009 the patient experienced a mild case of shingles. The nurse stated she had not been able to get in touch with the patient since he first contacted them about the shingles. The nurse stated that she was interested in the VZV analysis by PCR. The patient sought medical attention through a call to the nurse. At the time of this report the patient was recovering. Follow-up information received from a completed questionnaire indicated that he was a 72 year old male patient (previously reported as 71 year old), who was vaccinated with ZOSTAVAX (Merck) (Lot # 663673/1710X), 0.65 ml in the left arm. Concomitant therapy included ezetimibe (+) simvastatin (MSD), PRILOSEC, diclofenac, aspirin, VIAGRA, OSTEO-BI-FLEX, ICAPS, magnesium (unspecified) and hydroxyzine hydrochloride. It was stated that on 17-JAN-2009, the patient complain of pain and saw the physician on 21-JAN-2009. On 21-JAN-2009, the patient experienced mild case of shingles (onset date previously reported as 19-JAN-2009), which was diagnosed by the physician. A temperature measurement was performed and it was 97.2. On 21-JAN-2009, the patient experienced dermatome on the left back to chest (midline). On 28-JAN-2009, the patient experienced rash on left median side of back extending to left front side. Dried lesions with a few vesicles extending from left median back to around to left chest forming a continuous line of lesions. The patient saw the physician on 28-JAN-2009 and a temperature measurement was performed and it was 97.3. Pain level was determined as 9. The patient was enrolled in the Varicella Zoster Virus Identification program to identify if VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the OKA/Merck vaccine VZV strain. The sample of the lesion was collected on 30-JAN-2009. The sample was taken from a vesicle and a scrap of dried lesions. The patient stated that he did not remember if he had chickenpox and that was not exposed to chickenpox of herpes zoster recently. The PCR results for the specimen identified the presence of wild type VZV. Subsequently, the patient recovered. No further information is available. This is in follow-up to report (s) previously submitted on 3/27/2009.  Follow-up information received from a completed questionnaire indicated that he was a 72 year old male patient (previously reported as 71 year old), who was vaccinated with ZOSTAVAX (Merck) (Lot # 663673/1710X), 0.65 ml in the left arm.  Concomitant therapy included ezetimibe (+) simvastatin (MSD), PRILOSEC, diclofenac, aspirin, VIAGRA, OSTEO-BI-FLEX, ICAPS, magnesium (unspecified) and hydroxyzine hydrochloride.  It was stated that on 17-JAN-2009, the patient complain of pain and saw the physician on 21-JAN-2009.  On 21-JAN-2009, the patient experienced mild case of shingles (onset date previously reported as 19-JAN-2009), which was diagnosed by the physician.  A temperature measurement was performed and it was 97.2.  On 21-JAN-2009, the patient experienced dermatome on the left back to chest (midline).  On 28-JAN-2009, the patient experienced rash on left median side of back extending to left front side.  Dried lesions with few vesicles extending from left median back to around to left chest forming a continuous line of lesions.  The patient saw the physician on 28-JAN-2009 and a temperature measurement was performed and it was 97.3.  Pain level was determined as 9.  The patient was enrolled in the Varicella Zoster Virus Identification Program to identify if VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the OKA/Merck vaccine VZV strain.  The sample of the lesion was collected on 28-JAN-2009 and sent to laboratory on 29-JAN-2009 (previously reported as 30-JAN-2009).  The sample was taken from a vesicular lesion (site not specified) and a scrap of dried lesion.  The patient stated that he did not remember if her had chickenpox and that was not exposed to chickenpox or herpes zoster recently.  VZV DNA was amplified and the PCH results for the specimen identified the presence of wild type VZV.  Subsequently, the patient recovered.  Follow-up information received from the registered nurse indicated that he was a 71 year old patient (previously reported as 72 year old), who on 16-JAN-2009 at 14:08, was vaccinated with ZOSTAVAX (Merck).  There were no illnesses at the time of vaccination.  It was stated that the patient's events were treated with KENALOG, injection, PERCOCET, VALTREX, ZOVIRAX, cream.  On 28-JAN-2009, a swab of vesicle with a sterile swab was taken and placed in tube for viral specimen.  On 30-JAN-2009, a biopsy of dried lesion was taken.  They both were mailed on 02-FEB-2009 (previously reported as 29-JAN-2009).  No further information is available.  This is in follow-up to report (s) previously submitted on 3/27/2009; 6/24/2009. Follow-up information received from the registered nurse indicated that he was a 71 year old patient (previously reported as 72 year old), who on 16-JAN-2009 at 14:08, was vaccinated with ZOSTVAX (Merck). There were no illnesses at the time of vaccination. It was stated that the patient's events were treated with KENALOG, PERCOCET, VALTREX, ZOVIRAX, cream. On 28-JAN-2009, a biopsy of dried lesion was taken. They both were mailed on 02-FEB-2009 (previously reported as 29-JAN-2009). No further information is available.